Early detection of Alzheimer’s disease (AD) is crucial for patients to begin treatment early to slow the disease’s progression. While mild cognitive impairment (MCI) is considered an early translational stage of AD, clinically diagnosing MCI is difficult due to its inconsistent symptoms and the lack of standardized diagnostic tests. In this work, we proposed forward selection models to classify patients with AD, patients with MCI and healthy controls (HCs) based on single nucleotide polymorphisms (SNPs). In the proposed method, the initial SNP data were prescreened via genome-wide association studies with a suggestive significance threshold. Then, the qualified SNPs were reselected using the forward SNP selection algorithm to create classification models. Consequently, the forward selection models significantly outperformed the preselection models, those based on all prescreened SNPs, with an area under the precision-recall curve (AUPRC) value of 0.93 in the AD-HC classification, an AUPRC value of 0.94 in the MCI-HC classification, and an AUPRC value of 0.81 in the AD-MCI classification. Moreover, the proposed method could identify AD-associated and MCI-associated SNPs, which would support the clinical diagnosis of AD and MCI in the future.
Read full abstract